ReviewChemical Society reviews2019
Nanomedicine and macroscale materials in immuno-oncology.
Review in Chemical Society reviews, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 155 citations in OpenAlex.
- Smart microdevices for biomedical drug delivery: endogenous stimuli as the key to safer therapeutics.RSC advances · 2026Review
- Pan-cancer analysis of DLAT reveals it as a prognostic Biomarker involved in immune infiltration of liver hepatocellular carcinoma.Journal of Cancer · 2025Article
- Nanomaterials-mediated adenosine pathway inhibition for strengthening cancer immunotherapy.Theranostics · 2025Review
- Smart Cancer Nanomedicine for Synergetic Therapy.Current medicinal chemistry · 2025Review
- Assembly and biological functions of metal-biomolecule network nanoparticles formed by metal-phosphonate coordination.Science advances · 2024Article
- Forefronts and hotspots evolution of the nanomaterial application in anti-tumor immunotherapy: a scientometric analysis.Journal of nanobiotechnology · 2024Article
- Role of the gut microbiota in tumorigenesis and treatment.Theranostics · 2024Review
- Peptide-Decorated Degradable Polycarbonate Nanogels for Eliciting Antigen-Specific Immune Responses.International journal of molecular sciences · 2023Article
- Managing the immune microenvironment of osteosarcoma: the outlook for osteosarcoma treatment.Bone research · 2023Review
- Artificial and Naturally Derived Phospholipidic Bilayers as Smart Coatings of Solid-State Nanoparticles: Current Works and Perspectives in Cancer Therapy.International journal of molecular sciences · 2022Review
- SPI1 is a prognostic biomarker of immune infiltration and immunotherapy efficacy in clear cell renal cell carcinoma.Discover oncology · 2022Article
- Three-dimensional (3D) scaffolds as powerful weapons for tumor immunotherapy.Bioactive materials · 2022Review
- Nanotherapeutics Plus Immunotherapy in Oncology: Who Brings What to the Table?Pharmaceutics · 2022Review
- The Potential of Curcumin-Capped Nanoparticle Synthesis in Cancer Therapy: A Green Synthesis Approach.Nanomaterials (Basel, Switzerland) · 2022Review
- Recent Advances in Nanoparticles-Based Platforms Targeting the PD-1/PD-L1 Pathway for Cancer Treatment.Pharmaceutics · 2022Review
- Personalized cancer vaccines from bacteria-derived outer membrane vesicles with antibody-mediated persistent uptake by dendritic cells.Fundamental research · 2022Article
- Triggering Immune System With Nanomaterials for Cancer Immunotherapy.Frontiers in bioengineering and biotechnology · 2022Review
- Advances in Engineered Polymer Nanoparticle Tracking Platforms towards Cancer Immunotherapy-Current Status and Future Perspectives.Vaccines · 2021Review
- Nanotechnology synergized immunoengineering for cancer.European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V · 2021Review
- Deep exploration of random forest model boosts the interpretability of machine learning studies of complicated immune responses and lung burden of nanoparticles.Science advances · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 5 countries.
Funding
Abstract
Immunotherapy is revolutionizing the treatment of cancer. It can achieve unprecedented responses in advanced-stage patients, including complete cures and long-term survival. However, immunotherapy also has limitations, such as its relatively low response rates and the development of severe side effects. These drawbacks are gradually being overcome by improving our understanding of the immune system, as well as by establishing combination regimens in which immunotherapy is combined with other treatment modalities. In addition to this, in recent years, progress made in chemistry, nanotechnology and materials science has started to impact immuno-oncology, resulting in more effective and less toxic immunotherapy interventions. In this context, multiple different nanomedicine formulations and macroscale materials have been shown to be able to boost anti-cancer immunity and the efficacy of immunomodulatory drugs. We here review nanotechnological and materials chemistry efforts related to endogenous and exogenous vaccination, to the engineering of antigen-presenting cells and T cells, and to the modulation of the tumor microenvironment. We also discuss limitations, current trends and future directions. Together, the insights provided and the evidence obtained indicate that there is a bright future ahead for engineering nanomedicines and macroscale materials for immuno-oncology applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.